Mirum Pharmaceuticals Inc
MIRM
NASDAQ
Biotechnology
$100.64
USD
+1.87 (+1.89%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $6.43B
Volume 503.8K
Revenue
$618.07M
TTM
+44.0%
YoY
Gross Margin
82%
TTM
+3.4%
YoY
Net Income
$-860.21M
TTM
-1368.9%
YoY
Operating Cash Flow
$-227.27M
TTM
-2626.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 127.8 | 133.0 | 148.9 | 159.9 | 176.2 |
YoY Growth | +64.1% | +47.2% | +49.8% | +43.3% | +37.9% |
Cost of Revenue | 23.4 | 25.5 | 28.3 | 28.8 | 30.3 |
Gross Profit | 104.4 | 107.5 | 120.7 | 131.1 | 145.9 |
Selling, General & Administrative | 63.3 | 61.9 | 74.1 | 96.3 | 81.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 109.4 | 104.9 | 125.2 | 920.5 | 188.4 |
Operating Income | -5.0 | 2.6 | -4.6 | -789.5 | -42.5 |
EBITDA | 1.1 | 8.7 | 1.5 | -782.6 | -35.6 |
Other Income / Expense | 0.1 | 0.4 | -0.2 | 0.0 | -24.2 |
Total Other Income / Expense | -0.5 | 0.0 | -0.4 | -0.2 | -23.0 |
Income Before Income Taxes | -5.5 | 2.6 | -5.0 | -789.7 | -65.5 |
Income Taxes | 0.4 | -0.3 | 0.8 | 0.5 | 1.7 |
Net Income | -5.9 | 2.9 | -5.7 | -790.2 | -67.2 |
Consolidated Net Income / Loss | -5.9 | 2.9 | -5.7 | -790.2 | -67.2 |
Net Income Attributable to Common Shareholders | -5.9 | 2.9 | -5.7 | -790.2 | -67.2 |
Basic EPS | -$0.12 | $0.06 | -$0.11 | -$13.43 | -$1.06 |
Diluted EPS | -$0.12 | $0.05 | -$0.13 | -$13.43 | -$1.06 |
Basic Shares Outstanding | 49.7M | 50.6M | 51.5M | 58.9M | 63.4M |
Diluted Shares Outstanding | 49.7M | 57.0M | 45.2M | 58.9M | 63.4M |